{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpoliticos-pulse-check.simplecast.com%2Fepisodes%2Fwhats-new-in-psychedelics-research-vYUMxUSt","width":444,"version":"1.0","type":"rich","title":"What's new in psychedelics research","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/4da913b0-f9d2-4c36-aafd-0cefba14ffbc/53dd2434-9a18-4ec1-b716-3a0d79d20428/politico-pulse-check-audio-audio.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/388f72df-7fa6-4875-9d65-5c257f5b69f2\" height=\"200\" width=\"100%\" title=\"What&apos;s new in psychedelics research\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Erin Schumaker talks with host Ruth Reader about the prospect of developing next-generation non-hallucinogenic versions of drugs such as psilocybin to treat brain disorders like depression, post-traumatic stress disorder and addiction, and the regulatory barriers that researchers who want to study psychedelics are up against."}